Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

STAT

FEBRUARY 12, 2024

We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons.

Diabetes 285

Diabetes Vaccines Communication Hospitals 285

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 Dr Bhat : Chronic diseases where FDCs are employed include hypertension, diabetes, Human Immunodeficiency Virus (HIV) and tuberculosis (TB). New types of drugs, such as oral vaccines, will also be formulated as capsules. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines Diabetes 124

PharmaShots

APRIL 3, 2023

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

European Pharmaceutical Review

JUNE 27, 2022

The €156 million initiative identifies effective actions and the available legal and financial supporting tools across five main areas: cardiovascular diseases, diabetes, chronic respiratory diseases, mental health and neurological disorders, as well as their main contributing factors. Did you know, 1.7

Vaccines 110

Vaccines Communication Documentation Compounding 110

European Pharmaceutical Review

JANUARY 10, 2025

Eleven medicines, covering key areas such as gene therapy, as well as drugs for obesity and oncology, are anticipated to attain blockbuster status or be therapeutic game-changers globally within five years to 2030, according to the 2025 edition of the Drugs to Watch report.

Diabetes 59

Diabetes Vaccines 59

Express Pharma

JANUARY 3, 2025

Of the top 24 blockbuster drugs going off-patent during the patent cliff 2022-2030, 14 are biologics, as per a study conducted in August 2023 by the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Govt of India. per cent by 2030. billion by 2030. billion by 2030. per cent by 2026 and 37.5

Biosimilars 105

Biosimilars Vaccines Diabetes 105